Zero Candida Announces Successful Listing on Frankfurt Stock Exchange and Details of Investor Webinar

Zero Candida Canada United States of America United Kingdom British Columbia Israel

to register and submit questions.

https://us06web.zoom.us/meeting/register/Av2zeMAcTB-3HRKI8lYVGw

For those unable to attend, a recording of the webinar and additional materials will be made available on the Company's website.

About Zero Candida:

Zero Candida (ZCT) is a publicly traded FemTech company pioneering innovative solutions in women's health. The company is developing an AI-driven, tampon-like device that uses a therapeutic light source with a selected wave-length and intensity to effectively treat the Candida fungus with a demonstrated 99.999% success rate in POC. Vulvo-Vaginal Candidiasis ("VVC") affects about 75% of women globally, with 138 million women affected each year, and 492 million over their lifetime. Recurrent VVC (4 or more episodes per year) is increasingly documented to become drug resistant to existing treatments, since the root cause is poorly understood and addressed. ZCT has successfully completed a safety trial using its pre-clinical device in large animals (sheep), and is finalizing their device for human use in preparation for an upcoming clinical trial, that they secured both funding and agreements with leading hospitals in Israel and Europe for. The Company continues to grow its global patent portfolio with applications filed in the United States, Brazil and Europe, and was recently granted a final patent in South Africa. With hybrid medicine and technology-based diagnostics, ZCT is addressing unmet needs in women's healthcare and expanding access to underserved populations, bringing the field of gynecology into the 21st century. To learn more visit www.zero-candida.com.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward-Looking Statements

This news release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, are forward-looking statements. The Company provides no assurance that forward-looking statements and information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company does not undertake to update any forward-looking statements, other than as required by law. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Zero Candida. Readers are cautioned not to place undue reliance on forward-looking statements.

Contacts:

Victoria Gamble
[e-mail]
[phone]

Eli Ben Haroosh
CEO & Founder
[e-mail]

Logo - https://mma.prnewswire.com/media/2420533/4723164/ZERO_CANDIDA_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/zero-candida-announces-successful-listing-on-frankfurt-stock-exchange-and-details-of-investor-webinar-302353096.html

@ prnewswire.co.uk